Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults

Contributed by: PR Newswire

Tags

CSL-Seqirus-phase-3

More Like This

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Over 5 million under 65s with a long-term health condition could miss out flu vaccine

New survey reveals how older Brits are determined to dodge winter viruses to protect their independence and loved ones

Advancing Influenza Vaccine Development: Sino Biological Launches Antigens for the 2026-2027 Northern Hemisphere Influenza Vaccine Strains

PR Newswire associated0

Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of Revolutionary Universal Influenza Vaccine

PR Newswire associated0

Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.

Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)

New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization